Unity Biotechnology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UBX research report →
Range $1 – $4
Price Chart
About the company
Unity Biotechnology, Inc. is a biotechnology firm specializing in the development of therapeutic solutions aimed at slowing, halting, or even reversing age-associated diseases. Leading its pipeline, the drug candidate UBX1325 is currently undergoing Phase II clinical trials to treat age-related vision disorders, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
- CEO
- Anirvan Ghosh
- IPO
- 2018
- Employees
- 16
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on UBX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.44M
- P/E
- -0.13
- Fwd P/E
- 1.54
- PEG
- -0.02
- P/S
- 0.00
- P/B
- 0.52
- EV/EBITDA
- -0.77
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -148.97%
- ROIC
- -96.71%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-867,000+95.6%
- Op Income
- $-31,171,000
- Net Income
- $-25,990,000+34.8%
- EPS
- $-1.54+43.0%
- OCF Growth
- +46.0%
- FCF Growth
- +43.8%
- 52W High
- $3.10
- 52W Low
- $0.10
- 50D MA
- $0.66
- 200D MA
- $1.23
- Beta
- 1.06
- RSI (14)
- 18
- Avg Volume
- 761.63K
No earnings-call transcripts are available for UBX yet.
- Free Float
- 92.3%
- Shares Outstanding
- 17.21M
- Float Shares
- 15.88M
of shares held by institutions
60 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| 20/20 Capital Management, Inc. | 42.84K | ▲ 42.84K |
| Marshall Wace North America L.P. | 14.40K | 0 |
Held by 1 ETFs
Biggest fund positions in UBX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 27, 25 | Jalbert Craig R. | other | 0 |
| Apr 2, 25 | Nguyen Alexander Hieu | sell | 17,852 |
| Apr 2, 25 | Sullivan Lynne Marie | sell | 21,867 |
| Apr 2, 25 | Ghosh Anirvan | sell | 96,797 |
| Mar 28, 25 | Nguyen Alexander Hieu | other | 73,000 |
| Mar 28, 25 | Nguyen Alexander Hieu | other | 44,000 |
| Mar 27, 25 | Nguyen Alexander Hieu | sell | 1,954 |
| Mar 28, 25 | Sullivan Lynne Marie | other | 65,000 |
| Mar 28, 25 | Sullivan Lynne Marie | other | 106,000 |
| Mar 28, 25 | Ghosh Anirvan | other | 286,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our UBX coverage
Recent articles, reports, and earnings notes.
No research on UBX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate UBX report →UBX Tanzania Deepens Partnership with ACI Worldwide to Power the Next Phase of the Nation's Digital Economy
businesswire.com · May 21
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
globenewswire.com · May 1
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
globenewswire.com · Apr 22
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
zacks.com · Mar 25
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls
benzinga.com · Mar 24
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema
globenewswire.com · Mar 24
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025
globenewswire.com · Mar 23
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
globenewswire.com · Mar 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.